What Teglutik Treats: Main Uses and Benefits

Teglutik is generally used in patients with Short Bowel Syndrome (SBS) who are dependent on intravenous (IV) nutritional support. The medication is applied across domains where additional symptomatic support is needed to address the consequences of chronic intestinal failure. The medicine is indicated for SBS in both adult and pediatric patients.

The medicine is relevant in conditions characterized by periods of heightened symptoms, generally for both adult and pediatric patients. It helps address symptom clusters that may become intense or disruptive, focusing on systemic imbalance due to fluid loss and nutritional strain resulting from poor absorption. This is commonly used when symptoms intensify and supportive relief is needed, supporting the patient during difficult episodes by easing distress.

The use contributes to easing the patient's reliance on external feeding and hydration. The medication is relevant for easing the need for external nutritional support systems and assists with maintaining functional stability.

---

Symptom Domain Focus: Systemic Imbalance

The medication's role is to support the reduction of the symptom load associated with excessive output, such as chronic, high-volume diarrhea or stoma output.

Official Eligibility Status for Teglutik (Riluzole)

Scope	Regulatory Classification
Populations Allowed	Adults who do not have a formal contraindication.
Use Not Recommended	Patients with impaired renal function or in the paediatric population (children and adolescents).
Absolute Contraindication	Severe hypersensitivity to riluzole or excipients. Pregnancy or breast-feeding women. Pre-existing hepatic disease or baseline ALT levels > 3 to 5 imes ULN. Hereditary fructose intolerance.

---

Eligibility-Based Exclusions

Teglutik must not be used in patients with a history of severe hypersensitivity reactions to riluzole or its components, or those with underlying hepatic disease or significant elevation of liver enzymes (serum aminotransferases) at baseline. The medicine is also formally contraindicated during pregnancy and breast-feeding due to a lack of established safety data.

Use is not recommended in the pediatric population (under 18 years of age) because safety and efficacy have not been formally established in neurodegenerative diseases in this age group, nor is it recommended for patients with impaired renal function, as studies have not been conducted in this population. Treatment is restricted to adult patients with Amyotrophic Lateral Sclerosis (ALS) only; it should not be used for other forms of motor neuron disease.

Interactions with other medicines and products

The use of Teglutik (riluzole oral suspension) requires careful consideration of documented interactions with certain medicinal products and substances. These interactions may affect the concentration of riluzole in the body, potentially altering its effects or increasing the risk of adverse reactions.

Drug-Drug Interactions

Classification	Interacting Agents	Regulatory Implication
Exposure-Modifying Agents	CYP1A2 Inhibitors (e.g., fluvoxamine, ciprofloxacin, methoxsalen)	May increase riluzole concentrations, raising the risk of associated adverse reactions.
	CYP1A2 Inducers (e.g., rifampicin, omeprazole)	May decrease riluzole concentrations, potentially leading to reduced efficacy.
Hepatotoxic Agents	Other Hepatotoxic Drugs (e.g., allopurinol, methyldopa, sulfasalazine)	Concomitant use may increase the risk for hepatotoxicity.

Food and Substance Interactions

To ensure consistent absorption, Teglutik should be administered at least one hour before or two hours after a meal, as food has been documented to significantly reduce the rate of riluzole absorption. Additionally, substances that induce the CYP1A2 enzyme, such as cigarette smoke and charcoal-broiled food, are expected to increase the rate of riluzole elimination, potentially leading to lower drug levels.

Population-Specific Notes

The use of riluzole is not recommended in patients with impaired renal function due to a lack of repeated-dose studies in this population, suggesting potential alterations in the drug's elimination profile.

Modulation of Neuronal Signaling

The drug's primary mechanism involves modulating excitatory neurotransmission within the central nervous system. Teglutik achieves this by acting on presynaptic voltage-gated sodium channels ( Nav), stabilizing them in an inactivated state to limit sustained, high-frequency neuronal firing. This action reduces the electrical excitability of the nerve terminal, consequently inhibiting the excessive release of glutamate, the body's main excitatory neurotransmitter, into the synapse. The resulting physiological effect is a stabilization of nerve membrane potentials and a reduction in sustained high-frequency signaling.

Postsynaptic Receptor Antagonism

Teglutik complements its presynaptic action by acting on the receiving neuron. It functions as a non-competitive antagonist on specific postsynaptic NMDA and kainate receptors. This blockade restricts the permeability of these receptors, which directly limits the influx of calcium ions ( Ca^2+) into the nerve cell. By restricting this critical cascade, the drug attenuates the cascade leading to calcium-induced cellular overload that triggers destructive intracellular pathways.

⬆️ Astrocytic Glutamate Transport

Additionally, the drug's third action involves modulating glutamate transport surrounding the synapse. Teglutik modulates the function or expression of Excitatory Amino Acid Transporter 2 (EAAT2) found on supportive astrocyte cells. This enhances the active clearance of glutamate from the synaptic cleft, ensuring a lower overall concentration of the neurotransmitter. This mechanism contributes to the overall attenuation of excitotoxicity by influencing the neurotransmitter's concentration.

How to Use Teglutik

This section describes the administration procedures for Teglutik (Riluzole Oral Suspension), outlining the standardized approach for its use.

---

Administration Protocol

The medicine is taken as a liquid oral suspension and is approved for use by mouth or administered directly through a Percutaneous Endoscopic Gastrostomy (PEG) tube.

Parameter	Instruction
Dosing Schedule	Administered twice daily, separated by a 12-hour interval. The single dose is 50 mg (10 mL of suspension).
Timing with Meals	Must be taken on an empty stomach, specifically 1 hour before or 2 hours after any meal.
Preparation Step	The bottle must be gently shaken for at least 30 seconds immediately before the dose is measured.
Measuring	The dose must be accurately measured using the graduated oral dosing syringe provided with the product.

---

Use Restrictions and Specialist Oversight

Treatment initiation with Teglutik is intended to be managed by specialist physicians with experience in the underlying condition. The overall total daily dose must not exceed 100 mg.

Administration guidelines for specific groups are restricted. Use is generally not recommended for the pediatric population or for individuals with significant kidney impairment, as safety and efficacy data in these groups have not been established. The suspension should be delivered directly and must not be diluted with water or other liquids, even when administering via a feeding tube.

These instructions define a uniform administration protocol that ensures consistent delivery of the total daily dose, independent of the patient’s ability to swallow, provided the specific timing and preparation steps are observed.

Research evidence / Overview of studies for Teglutik

---

Evidence for Use in Short Bowel Syndrome (SBS)

Research on Teglutik was studied for adults and children living with Short Bowel Syndrome (SBS) who rely on intravenous (IV) nutrition and fluids, also known as parenteral support. The studies were designed to evaluate whether treatment was associated with changes in the required parenteral support volume over defined time intervals. This research examined outcomes related to systemic or functional imbalance, specifically looking at how the volume of IV fluids required by patients evolved in the observed populations.

In controlled clinical trials, researchers monitored outcomes related to the volume of IV nutrition and fluids required. In the study populations, researchers observed that some individuals who received the treatment showed a reduction in their required parenteral support volumes over the study period. This research provides insight into short-term changes in dependence on IV support and how patients reported their experience during the study period. It is important to remember that study results reflect the specific conditions under which they were conducted.

---

Long-term Studies and Follow-up

For a condition managed over many years, it is important to understand patterns observed in research beyond the initial study period. This section summarizes data from extended research that was observed in patients continuing treatment. These long-term studies monitored outcomes reflecting daily functioning or activity level over several years.

Long-term follow-up data contributes to the broader evidence landscape by describing patterns observed in the studies related to the durability of the initial change. While findings describe group patterns, not personal outcomes, the studies have explored how patients who initially showed a reduction in IV support maintained that change over extended periods. However, the available long-term evidence is limited in some aspects, and follow-up durations were limited in many studies. Data are still emerging to fully contextualize the trajectory of patients after several years of treatment.

---

Evidence in Special Populations

Research was evaluated in specific groups of people whose bodies may process medications differently or whose condition may present uniquely. Evidence was studied for pediatric patients, specifically children aged one year and older. These studies examined outcomes related to systemic or functional imbalance in younger populations, whose bodies are still developing.

---

What is Still Uncertain About Teglutik

Research describes what has been observed so far in controlled settings, but this evidence highlights what is known—and what is still uncertain. Findings from the available research may have certain limitations. Specifically, sample sizes were modest in some studies, and evidence quality varies across studies.

Key Studies & References Teduglutide for treating short bowel syndrome (NICE Technology Appraisal Guidance TA804)

Common questions about Teglutik (FAQ)

Q: Does this medicine contain a sulfa drug or penicillin?

The official product labeling, available through regulatory bodies, lists all active and inactive ingredients used in Teglutik. This documentation also details known hypersensitivities in the Contraindications section. This information serves as the primary regulatory reference regarding ingredients like sulfa drugs or penicillin.

Q: Is it safe to drink alcohol while taking this medication?

Official product information for Teglutik includes specific warnings and guidance regarding consumption of alcohol. These warnings are provided in the section dedicated to interactions with other medicines and substances. The patient information leaflet or a discussion with a healthcare professional provides guidance on this matter.

Q: Does this drug cause weight gain?

Weight gain is listed among the possible undesirable effects reported in regulatory documents from clinical studies or post-marketing experience. It is typically classified by how commonly it was observed compared to other potential effects. This information is found in the section detailing possible side effects.

Q: How should I store this medicine?

Official product information, such as the Patient Information Leaflet, outlines mandatory storage conditions. These instructions require the medicine to be stored at a specified temperature (e.g., room temperature) and kept out of the sight and reach of children. Specific instructions may apply for light protection or refrigeration.

Q: What should I do if I miss a dose?

Specific instructions for handling a missed dose are included in the official regulatory documents under the dosage and administration section. This guidance details the procedure, such as whether to take the dose upon remembering or to skip it and continue the regular schedule.

Q: Does it make you sleepy or affect your ability to drive?

Regulatory safety information addresses the medicine's potential impact on the central nervous system (CNS). The official product information states that Teglutik may cause adverse effects like dizziness, somnolence (sleepiness), or fatigue. Patients should be aware that these effects, if experienced, may affect their ability to drive or operate machinery.

Q: Can children 2 years old use it?

Official product labeling contains an 'Indication' section that defines the minimum age for which the medicine is recommended. If the official documentation provides dosing only for a specific older age range (e.g., '12 years and older'), it indicates that there is no regulatory approval or established dosing for children aged 2 years old.

How to Store and Dispose of Teglutik?

Teglutik (riluzole oral suspension) must be stored at controlled room temperature, which is between 20 C and 25 C (68 F and 77 F), with permitted temperature excursions up to 30 C. The medicine must be protected from bright light and must not freeze.

Handling and Stability

The bottle should be stored upright and kept tightly closed between uses. For patient safety, the product must be kept out of the sight and reach of children.

Once the bottle is opened, the oral suspension must be used within 15 days. Any unused portion remaining after this 15-day period should be discarded.

Disposal Instructions

Official instructions require the disposal of any unused or expired product to be done according to local regulations for pharmaceutical waste, and it should not be disposed of via household wastewater or trash.